Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01520077 · ClinicalTrials.gov registry record · Phase 1
Vytorin in the Treatment of Alopecia Areata
A Phase 1 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01520077 is a Phase 1 study that has completed, run by University of Miami. The registered enrollment target is 29 participants.
The verdict
NCT01520077, a Phase 1 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
Subjects, non pregnant/lactating and over 18years old, with 40% alopecia areata will take vytorin (statin/ezetimibe) for 24 or 52 weeks and be monitored for hair regrowth. The investigators hypothesize that Vytorin medication may have an effect on the inflammatory process of alopecia areata. Inactivating the inflammatory process may help in permitting hair regrowth in those subjects.
Interventions
- DRUG vytorin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01520077
The ClinicalTrials.gov registry entry for NCT01520077 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vytorin is the first listed.
NCT01520077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01520077 about?
NCT01520077 is a clinical study titled "Vytorin in the Treatment of Alopecia Areata". Subjects, non pregnant/lactating and over 18years old, with 40% alopecia areata will take vytorin (statin/ezetimibe) for 24 or 52 weeks and be monitored for hair regrowth. The investigators hypothesize that Vytorin medication may have an effect on the inflammatory process of alopecia areata. Inacti...
What is the current status of trial NCT01520077?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2011-07. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01520077?
The interventions under investigation include: vytorin (DRUG).
Who is sponsoring clinical trial NCT01520077?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.